Promising cocktail targets tough lung cancer

NCT ID NCT06838208

Recruiting now Disease control Sponsor: Anhui Provincial Cancer Hospital Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This study tests whether adding an immunotherapy drug (tislelizumab) to standard chemotherapy and radiation can help people with extensive small cell lung cancer live longer without their cancer getting worse. About 56 adults who have not had prior treatment for this advanced cancer will receive the combination. The main goal is to see how long the cancer stays under control.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: tislelizumab (an immunotherapy drug) combined with chemotherapy (carboplatin or cisplatin plus etoposide) and radiotherapy
What this could lead to: If successful, this could offer a new first-line treatment option that may help control extensive small cell lung cancer for longer than current therapies.
What could go wrong: This is an early Phase 2 trial with only 56 participants, so results may not apply to all patients. The combination also carries risks of side effects from chemotherapy, immunotherapy, and radiation.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for EXTENSIVE STAGE SMALL CELL LUNG CANCER (ES-SCLC) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

EXTENSIVE STAGE SMALL CELL LUNG CANCER (ES-SCLC)

Contacts and locations

Locations

Anhui Cancer Hospital
RECRUITING

Hefei, Anhui, 230031, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.